Andere Kunden interessierten sich auch für
![Optimizing the]( "Optimizing the")
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery162,99 €![Pharmaceutical Profiling in Drug Discovery for Lead Selection]( "Pharmaceutical Profiling in Drug Discovery for Lead Selection")
Pharmaceutical Profiling in Drug Discovery for Lead Selection274,99 €![Ligand-Macromolecular Interactions in Drug Discovery]( "Ligand-Macromolecular Interactions in Drug Discovery")
Ligand-Macromolecular Interactions in Drug Discovery103,99 €![Fabrication of dosage form leads to decrease in cost of the therapy]( "Fabrication of dosage form leads to decrease in cost of the therapy")
Fabrication of dosage form leads to decrease in cost of the therapy32,99 €![Drugs from Nature: Targets, Assay Systems and Leads]( "Drugs from Nature: Targets, Assay Systems and Leads")
Drugs from Nature: Targets, Assay Systems and Leads125,99 €![Formulation and drug releasing properties of Gastro retentive tablets]( "Formulation and drug releasing properties of Gastro retentive tablets")
Formulation and drug releasing properties of Gastro retentive tablets29,99 €![The Business of Bioscience]( "The Business of Bioscience")
The Business of Bioscience125,99 €
Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, "drug-like" properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.